Literature DB >> 23931841

Beyond identification: emerging and future uses for MALDI-TOF mass spectrometry in the clinical microbiology laboratory.

Mari L DeMarco1, Bradley A Ford.   

Abstract

The routine use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) has revolutionized microorganism identification in the clinical microbiology laboratory. Building from these now common microorganism identification strategies, this review explores future clinical applications of MALDI-TOF MS. This includes practical approaches for laboratorians interested in implementing direct identification processing methods for MALDI-TOF detection of microbes in bloodstream infection (BSI) and urinary tract infection (UTI), as well as, post-analytical approaches for classifying MALDI-TOF spectral data to detect characteristics other and species-level identification (e.g. strain-level classification, typing, and resistance mechanisms).
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimicrobial susceptibility testing; Bacteremia; Bloodstream infection; Direct identification; MALDI-TOF; Machine learning; Mass spectrometry; Urinary tract infection

Mesh:

Year:  2013        PMID: 23931841     DOI: 10.1016/j.cll.2013.03.013

Source DB:  PubMed          Journal:  Clin Lab Med        ISSN: 0272-2712            Impact factor:   1.935


  13 in total

Review 1.  Mass spectrometry tools and workflows for revealing microbial chemistry.

Authors:  Tal Luzzatto-Knaan; Alexey V Melnik; Pieter C Dorrestein
Journal:  Analyst       Date:  2015-08-07       Impact factor: 4.616

2.  Identification of Rare Bacterial Pathogens by 16S rRNA Gene Sequencing and MALDI-TOF MS.

Authors:  Percy Schröttner; Florian Gunzer; Jana Schüppel; Wolfram W Rudolph
Journal:  J Vis Exp       Date:  2016-07-11       Impact factor: 1.355

3.  Identification of Low-Level Vancomycin Resistance in Staphylococcus aureus in the Era of Informatics.

Authors:  Bradley A Ford
Journal:  J Clin Microbiol       Date:  2016-02-10       Impact factor: 5.948

4.  Clinical Evaluation of a Blood Assay to Diagnose Paucibacillary Tuberculosis via Bacterial Antigens.

Authors:  Chang Liu; Christopher J Lyon; Yang Bu; Zaian Deng; Elisabetta Walters; Yan Li; Liqun Zhang; Anneke C Hesseling; Edward A Graviss; Ye Hu
Journal:  Clin Chem       Date:  2018-01-18       Impact factor: 8.327

Review 5.  Emerging rapid resistance testing methods for clinical microbiology laboratories and their potential impact on patient management.

Authors:  Hagen Frickmann; Wycliffe Omurwa Masanta; Andreas E Zautner
Journal:  Biomed Res Int       Date:  2014-09-17       Impact factor: 3.411

Review 6.  Recent development of mass spectrometry and proteomics applications in identification and typing of bacteria.

Authors:  Keding Cheng; Huixia Chui; Larissa Domish; Drexler Hernandez; Gehua Wang
Journal:  Proteomics Clin Appl       Date:  2016-02-02       Impact factor: 3.494

7.  Personalized Proteomics: The Future of Precision Medicine.

Authors:  Trevor T Duarte; Charles T Spencer
Journal:  Proteomes       Date:  2016-10-01

8.  1H NMR spectroscopy-based metabolomics analysis for the diagnosis of symptomatic E. coli-associated urinary tract infection (UTI).

Authors:  Milena Lussu; Tania Camboni; Cristina Piras; Corrado Serra; Francesco Del Carratore; Julian Griffin; Luigi Atzori; Aldo Manzin
Journal:  BMC Microbiol       Date:  2017-09-21       Impact factor: 3.605

9.  Head-to-head comparison of Microflex LT and Vitek MS systems for routine identification of microorganisms by MALDI-TOF mass spectrometry in Chile.

Authors:  Lorena Porte; Patricia García; Stephanie Braun; María Teresa Ulloa; Mónica Lafourcade; Alisson Montaña; Carolina Miranda; Gerardo Acosta-Jamett; Thomas Weitzel
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

Review 10.  Proteomics As a Tool for Studying Bacterial Virulence and Antimicrobial Resistance.

Authors:  Francisco J Pérez-Llarena; Germán Bou
Journal:  Front Microbiol       Date:  2016-03-31       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.